Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
Cipla completes transfer of Generics Business Undertaking
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The plant will drive pharmaceutical innovation in the Northeastern India
BHL will undertake the development and supply of these molecules
The facility will accommodate over 1,500 employees
Subscribe To Our Newsletter & Stay Updated